-
1Academic Journal
Συγγραφείς: V. B. Matveev, A. S. Markova, В. Б. Матвеев, А. С. Маркова
Πηγή: Cancer Urology; Том 12, № 2 (2016); 84-91 ; Онкоурология; Том 12, № 2 (2016); 84-91 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-2
Θεματικοί όροι: Элигард, hormone therapy, testosterone, prostate specific antigen, luteinising hormone-releasing hormone agonists, leuprorelin acetate, Eligard, гормональная терапия, тестостерон, простатический специфический антиген, агонисты лютеинизирующего гормона рилизинг-гормона, лейпрорелина ацетат
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/580/552; https://oncourology.abvpress.ru/oncur/article/view/580/567; Состояние онкологической помощи в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2015. 236 с. [Cancer care status in 2014. Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: P.A. Herzen МSROI, 2015. 236 p. (In Russ.)].; Guidelines on Prostate Cancer. European Association of Urology (EAU). 2015. 137 p.; Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036–42.; Akaza H., Hinotsu S., Usami M. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, doubleblind, randomized study for survival. Cancer 2009;115(15):3437–45.; Schmitt B., Bennett C., Seidenfeld J. et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;(2):CD001526.; Tsushima T., Nasu Y., Saika T. et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int 2001;66(3):135–9.; Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11): 1531–8.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566–77.; Hedlund P.O., Damber J.E., Hagerman I. et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42(3):220–9.; Crawford E.D., Moul J.W., Sartor O., Shore N.D. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin. Drug Metab. Toxicol 2015;11(9):1465–74.; Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6): 1021–4.; Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10): 983–92.; Ryan C.J., Smith M.R., Fizazi K. et al. Final overall survival (OS) analysis of COUAA- 302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Ann Oncol 2014;25:iv255–79.; Klotz L., O’Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151–6.; Hussain M., Tangen C.M., Higano C. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic rostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175(2): 533–6.; Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urol 2011;11:15.; Braeckman J., Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo- Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014;10(3);477–83.; https://oncourology.abvpress.ru/oncur/article/view/580
-
2Academic Journal
Συγγραφείς: G. P. Kolesnikov, Г. П. Колесников
Πηγή: Cancer Urology; Том 11, № 3 (2015); 92-95 ; Онкоурология; Том 11, № 3 (2015); 92-95 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-3
Θεματικοί όροι: эффективность и безопасность терапии, hormone therapy, luteinizing hormone-releasing hormone agonists, Buserelin, prostate-specific antigen, testosterone, efficiency and safety of therapy, гормональная терапия, агонисты лютеинизирующего гормона рилизинг-гормона, Бусерелин, простат-специфический антиген, тестостерон
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/494/460; Anderson J., Abrahamsson P.A., Crawford D. et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy. BJU Int 2008;101: 1497–501.; Heidenreich A., Pfister D., Ohlamann C.H. et al. Androgen deprivation for advanced prostate cancer. Urologe 2008;47:270– 83.; Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.А. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. [Malignant neoplasms in Russia in 2012 (morbidity and mortality). Eds. by A.D. Kaprin, V.V. Starinsky, G.A. Petrova. M.: FSBE “P.A. Hertzen Moscow Cancer Research Institute” of the Ministry of Health of Russia, 2014. (In Russ.)].; Мишугин С.В., Мордовин А.А., Грицкевич А.А., Русаков И.Г. Медикаментозная кастрация в лечении распространенных форм рака предстательной железы. Роль бусерелина. Медицинский совет 2014;8:3–6. [Mishugin S.V., Mordovin A.A., Gritskevich A.A., Rusakov I.G. Medical Castration in Treatment of Most Distributed Forms of Prostate Cancer. Role of Buserelin. Medical Council (Meditsinskiy Sovet) 2014;8:3–6.(In Russ.)].; Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М., 2013. Kaprin A.D., Starinskiy V.V., Petrova G.V. Status of Oncology Aid to the Population of Russia in 2012. Moscow, 2013. (In Russ.)].; Бабаев Р., Матвеев В.Б., Волкова М.И. Факторы прогноза выживаемости больных распространенным раком предстательной железы, получающих гормонотерапию. Онкоурология 2011;2:78–83. [Babayev R., Matveyev V.B., Volkova M.I. Factors of Survival Prediction of Patients with Advanced Prostate Cancer That Receive Hormone Therapy. Oncourology (Onkourologiya) 2011;(2):78–83.(In Russ.)].; Нюшко К.М., Алексеев Б.Я., Калпинский А.С., Каприн А.Д. Антагонисты лютеинизирующего гормона рилизинг-гормона у больных раком предстательной железы. Стандартный подход и результаты инновационных исследований. Онкоурология 2014;4:70–4. [Nyushko K.M., Alexeev B.Y., Kalpinsky A.S., Kaprin A.D. Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. Standard approach and results of innovational studies. Onkourologiya = Oncourology 2014;4:70–4. (In Russ.)].; Рапопорт Л.М., Демидко Ю.Л. Применение бусерелина-депо – агониста гонадотропин-рилизинг-гормона в лечении рака простаты. Андрология и генитальная хирургия 2014;3:2–7. [Rapoport L.M., Demidko Yu.L. Application of Buserelin- Depo: Agonist of Gonadotropin Releasing Hormone in Treatment of Prostate Cancer. Andrology and Genital Surgery (Andrologiya i Genitalnaya Khirurgiya) 2014;3:2–7. (In Russ.)].; Сивков А.В., Матвеев В.Б., Бухаркин Б.В. и др. Результаты длительного применения агониста гонадотропин-рилизинг-гормона бусерелина-депо у больных раком предстательной железы. Consilium Medicum 2005;7(7):591–5. [Sivkov A.V., Matveyev V.B., Bukharkin B.V., et al. Results of Long-Term Application of Agonist of Gonadotropin Releasing Hormone of Buserelin-Depo of Patients with Prostate Cancer. Consilium Medicum 2005;7(7):591–5. (In Russ.)].; Копыльцов Е.И., Леонов О.В., Кривоногов И.И. и др. Отечественный депонированный лекарственный препарат в лечении больных раком предстательной железы. Онкоурология 2005. Тезисы 6-й Всерос. научно-практ. конференции «Актуальные вопросы лечения онкоурологических заболеваний». С. 94–5. [Kopyltsov E.I., Leonov O.V., Krivonogov I.I., et al. Domestic Deposited Drug in Treatment of Patients with Prostate Cancer. Oncourology (Onkourologiya) 2005. Abstracts of the 6th All-Russian Scientific Conference “Actual Problems of Treatment of Oncourological Diseases”. pp. 94–95. (In Russ.)].; https://oncourology.abvpress.ru/oncur/article/view/494
-
3Academic Journal
Πηγή: Онкоурология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, рак предстательной железы, гормональная терапия, тестостерон, простатический специфический антиген, агонисты лютеинизирующего гормона рилизинг-гормона, лейпрорелина ацетат, Элигард, 3. Good health
Περιγραφή αρχείου: text/html
-
4Academic Journal
Συγγραφείς: I. G. Rusakov, B. Ya. Alekseyev, K. M. Nyushko, И. Г. Русаков, Б. Я. Алексеев, К. М. Нюшко
Πηγή: Cancer Urology; Том 5, № 3 (2009); 56-60 ; Онкоурология; Том 5, № 3 (2009); 56-60 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2009-5-3
Θεματικοί όροι: Люкрин-депо, luteinizing hormone-releasing hormone agonists, Lucrin-depot, агонисты лютеинизирующего гормона рилизинг-гормона
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/267/284; Ries L.A.G., Kosary C.L., Hankey B.F. et al. SEER Cancer Statistics Review 1973—1995. Bethesda, MD: National Cancer Institute, 1998.; Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2009.; Матвеев В.Б. Клиническая онкоурология. М., 2003. с. 525—70.; Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2003; 169(3):1090.; Partin A.W., Kattan M.W., Subong E.N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445—51.; Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385—402.; Daneshgari F., Crawford E.D. Endocrine therapy of advanced prostate cancer. Cancer 1993;71:1089—97.; Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360(9327):103—8.; Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85—31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937—46.; Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243—52.; Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase III RTOG 85—31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.; Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472—9.; Seruga B., Tannock I.F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008;5(10):574—6.; Labrie F., Belanger A., Dupont A. et al. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16(6):475—92.; Chrisp P., Sorkin E.M. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991;1:487—509.; Sharifi R., Ratanwong C., Jung A., et al. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev 1997;28:121—36.; Togushi H. Formulation study of leuprorelin acetate to improve clinical performance. Clin Ther 1992;14:121—30.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533—6.; Tunn U.W., Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis 2009;12(1): 83—7.; Berges R., Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006;22(4):649—55.; Tunn U.W., Kurek R., Renneberg H. et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35(Suppl 1):27—31.; Gleave M.E., Goldenberg S.L., Chin J.L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166(2):500—6.; Soloway M.S., Pareek K., Sharifi R. et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002;167(1):112—6.; Montgomery B.S., Borwell J.P., Higgins D.M. Does needle size matters? Patient experience with luteinizing hormone releasing hormone analogue. Prostate Cancer Prostatic Dis 2005;8: 66—8.; Heyns C.F., Simonin M.P., Grosgurin P. et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003;92(3):226—31.; https://oncourology.abvpress.ru/oncur/article/view/267
-
5Academic Journal
Συγγραφείς: Русаков, И., Алексеев, Борис, Нюшко, К.
Θεματικοί όροι: РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, АГОНИСТЫ ЛЮТЕИНИЗИРУЮЩЕГО ГОРМОНА РИЛИЗИНГ-ГОРМОНА, ЛЮКРИН-ДЕПО
Περιγραφή αρχείου: text/html
-
6Academic Journal
Πηγή: Онкоурология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, 3. Good health, РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, АГОНИСТЫ ЛЮТЕИНИЗИРУЮЩЕГО ГОРМОНА РИЛИЗИНГ-ГОРМОНА, ЛЮКРИН-ДЕПО
Περιγραφή αρχείου: text/html
